Achieving blood pressure goals: Should angiotensin II receptor blockers become first-line treatment in hypertension?

Journal of Hypertension

Volumn 27, Issue SUPPL. 5, 2009, Pages

  Weber, Michael ^a,b  

^a SUNY Downstate Medical Center   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Angiotensin II receptor blocker; Antihypertensive; Blood pressure; Hypertension; ONTARGET; Telmisartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; NITRENDIPINE; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; ETHNICITY; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERTENSION; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; HUMANS; HYPERTENSION; RAMIPRIL; TREATMENT OUTCOME;

EID: 70349298656     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000357903.93951.73     Document Type: Review

References (24)

1. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
2. White W.B. Weber M.A. Davidai G. Neutel J.M. Bakris G.L. Giles T. Ambulatory blood pressure monitoring in the primary care setting: Assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 trial Blood Pressure Monitoring 2005 10 3 157-163 DOI 10.1097/00126097-200506000-00008 2 White WB, Weber MA, Davidai G, Neutel JM, Bakris GL, Giles T. Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit 2005; 10:157-163. (Pubitemid 40863089)
3. Lacourciere Y. Lenis J. Orchard R. Lewanczuk R. Houde M. Pesant Y. Wright J. Wilson T. Martin K. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine Blood Pressure Monitoring 1998 3 5 295-302 3 Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3:295-302. (Pubitemid 29012045)
4. White WB. Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit 1997; 2:47-51.
5. Kario K. Pickering T.G. Umeda Y. Hoshide S. Hoshide Y. Morinari M. Murata M. Kuroda T. Schwartz J.E. Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study Circulation 2003 107 10 1401-1406 DOI 10.1161/01.CIR.0000056521.67546.AA 5 Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406. (Pubitemid 36350739)
6. Williams B, Gosse P, Lowe L, Harper R, on behalf of the PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006; 24:193-200.
7. Chrysant S.G. Melino M. Karki S. Lee J. Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study Clinical Therapeutics 2008 30 4 587-604 DOI 10.1016/j.clinthera.2008.04.002, PII S0149291808001410 7 Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30:587-604. (Pubitemid 351680489)
8. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, et al. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005; 7:578-586.
9. Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, et al. Efficacy and safety of fixed combinations of irbesartan/ hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol 2008; 17: 27-36.
10. Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris GL, Cushman WC, et al. Irbesartan/HCTZ fixed combinations in patients of different racial/ ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006; 98:618-626.
11. Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) 2006; 8:470-480.
12. Weber M.A. Julius S. Kjeldsen S.E. Brunner H.R. Ekman S. Hansson L. Hua T. Laragh J.H. McInnes G.T. Mitchell L. Plat F. Schork M.A. Smith B. Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial Lancet 2004 363 9426 2049-2051 DOI 10.1016/S0140-6736(04)16456-8, PII S0140673604164568 12 Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363:2049-2051. (Pubitemid 38781107)
13. Dahlof B. Devereux R.B. Kjeldsen S.E. Julius S. Beevers G. De Faire U. Fyhrquist F. Ibsen H. Kristiansson K. Lederballe-Pedersen O. Lindholm L.H. Nieminen M.S. Omvik P. Oparil S. Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 2002 359 9311 995-1003 DOI 10.1016/S0140-6736(02)08089-3 13 Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
14. Schrader J. Luders S. Kulschewski A. Hammersen F. Plate K. Berger J. Zidek W. Dominiak P. Diener H.C. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES) Stroke 2005 36 6 1218-1224 DOI 10.1161/01.STR.0000166048.35740.a9 14 Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226. (Pubitemid 40798742)
15. Staessen J.A. Fagard R. Thijs L. Celis H. Arabidze G.G. Birkenhager W.H. Bulpitt C.J. De Leeuw P.W. Dollery C.T. Fletcher A.E. Forette F. Leonetti G. Nachev C. O' Brien E.T. Rosenfeld J. Rodicio J.L. Tuomilehto J. Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension Lancet 1997 350 9080 757-764 DOI 10.1016/S0140-6736(97)05381-6 15 Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764. (Pubitemid 27387202)
16. Pfeffer M.A. Swedberg K. Granger C.B. Held P. McMurray J.J.V. Michelson E.L. Olofsson B. Ostergren J. Yusuf S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme Lancet 2003 362 9386 759-766 DOI 10.1016/S0140-6736(03)14282-1 16 Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362:759-766. (Pubitemid 37093915)
17. Wachtell K. Lehto M. Gerdts E. Olsen M.H. Hornestam B. Dahlof B. Ibsen H. Julius S. Kjeldsen S.E. Lindholm L.H. Nieminen M.S. Devereux R.B. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End point reduction in hypertension (LIFE) study Journal of the American College of Cardiology 2005 45 5 712-719 DOI 10.1016/j.jacc.2004.10.068 17 Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losarían Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712-719. (Pubitemid 40282586)
18. Healey J.S. Baranchuk A. Crystal E. Morillo C.A. Garfinkle M. Yusuf S. Connolly S.J. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis Journal of the American College of Cardiology 2005 45 11 1832-1839 DOI 10.1016/j.jacc.2004. 11.070, PII S0735109705005358 18 Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839. (Pubitemid 40789940)
19. Madrid AH, Peng J, Zamora J, Marin I, Bernai E, Escobar C, et al. The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol 2004; 27:1405-1410.
20. Soran H, Ziglam H, Al Najjar M, Younis N. The role of the renin angiotensin system blocking in the management of atrial fibrillation. Acta Cardiol 2008; 63:457-465.
21. Anand K. Mooss A.N. Hee T.T. Mohiuddin S.M. Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation American Heart Journal 2006 152 2 217-222 DOI 10.1016/j.ahj.2006.01.007, PII S0002870306000585 21 Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. Am Heart J 2006; 152:217-222. (Pubitemid 44093401)
22. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials Lancet 2003 362 9395 1527-1535 DOI 10.1016/S0140-6736(03) 14739-3 22 Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 382:1527-1535. (Pubitemid 37410190)
23. Julius S. Kjeldsen S.E. Weber M. Brunner H.R. Ekman S. Hansson L. Hua T. Laragh J. McInnes G.T. Mitchell L. Plat F. Schork A. Smith B. Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial Lancet 2004 363 9426 2022-2031 DOI 10.1016/S0140-6736(04)16451-9, PII S0140673604164519 23 Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031. (Pubitemid 38781102)
24. Schumacher H, Maneia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press Suppl 2008; 1:32-40.